G40.83
Dravet syndrome
Clinical Classification Guidelines
Inclusion Terms
- Polymorphic epilepsy in infancy (PMEI)
- Severe myoclonic epilepsy in infancy (SMEI)
Medical Intelligence & Overview
Dravet syndrome, also known as severe myoclonic epilepsy in infancy (SMEI), is a rare and severe form of epilepsy that begins in the first year of life. Recognized by the ICD-10 code G40.83, this condition is characterized by frequent seizures and a variety of developmental challenges. It is a complex neurological disorder that requires careful management to improve quality of life for those affected.
Causes & Symptoms
Clinical Causes: Genetic mutations, most often in the SCN1A gene, which influence nerve signaling in the brain. De novomutations that are spontaneous and not inherited from parents. In some cases, no familial history of epilepsy is present. Environmental factors generally do not cause Dravet syndrome, though seizure triggers like fever or flashing lights may influence seizure activity.
Key Symptoms: Prolonged seizures, often occurring in the first year of life. Frequent myoclonic jerks—sudden, quick muscle spasms. Clonic seizures—repetitive jerking movements. Tonic seizures—stiffening of muscles causing rigidity. Focal seizures involving specific areas of the brain. Developmental delays or regression, particularly after the onset of seizures. Hypotonia or decreased muscle tone. Sensitivity to light or visual stimuli, triggering certain seizures. Behavioral challenges, including hyperactivity or autistic-like features in some children. Increased risk of sudden unexpected death in epilepsy (SUDEP) in severe cases.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Dravet syndrome involves a combination of clinical observation and tests. Medical professionals typically perform the following assessments: - Detailed medical history, focusing on seizure patterns and developmental milestones. - EEG (electroencephalogram) to detect characteristic abnormal brain activity. - Genetic testing to identify mutations in the SCN1A gene or other related genes. - Blood tests and neuroimaging as needed to rule out other conditions. Early diagnosis is crucial to managing symptoms effectively and implementing appropriate interventions.
Treatment Protocols: Managing Dravet syndrome can be complex and involves a multidisciplinary approach. Common strategies include: - Antiepileptic medications tailored to control seizures, such as stiripentol, valproate, and clobazam. - Ketogenic diet, a high-fat, low-carbohydrate diet that may reduce seizure frequency. - Behavioral therapies to address developmental and behavioral challenges. - Physical and occupational therapy to support motor and cognitive development. - Safety measures to prevent injury during seizures. - Regular monitoring by neurology specialists to adjust treatment plans. While there is currently no cure for Dravet syndrome, ongoing research continues to explore new treatment options to improve outcomes for affected individuals.
Clinical Advice & FAQs
Billing Guidance
Is G40.83 a billable ICD-10 code?
Yes, G40.83 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G40.83?
Clinical documentation must specify the nature of Dravet syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
